Management of hyperuricemia with rasburicase review

Nucleosides, Nucleotides and Nucleic Acids

Volumn 23, Issue 8-9, 2004, Pages 1431-1440

  De Bont, J M ^a   Pieters, R ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Hematological malignancies; Rasburicase; Tumor lysis

Indexed keywords

ALLANTOIN; ALLOPURINOL; CALCIUM PHOSPHATE; HYPOXANTHINE; RASBURICASE; URATE OXIDASE; URIC ACID; XANTHINE; XANTHINE OXIDASE INHIBITOR;

ADULT; ALKALINIZATION; CHILD; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; ENZYME INHIBITION; HUMAN; HYPERURICEMIA; KIDNEY CALCIFICATION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREVENTIVE MEDICINE; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; URINARY EXCRETION;

ALLOPURINOL; ANTIMETABOLITES; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; FREE RADICAL SCAVENGERS; HUMANS; HYPERURICEMIA; HYPOXANTHINE; TIME FACTORS; TUMOR LYSIS SYNDROME; URATE OXIDASE; URIC ACID; XANTHINE OXIDASE;

EID: 10344260907     PISSN: 15257770     EISSN: None     Source Type: Journal    
DOI: 10.1081/NCN-200027656     Document Type: Conference Paper

References (18)

1. Jeha, S. Tumor lysis syndrome. Semin. Hematol. 2001, 38 (4 Suppl 10), 4-8.
2. Kelly, K.M.; Lange, B. Oncologic emergencies. Pediatr. Clin. North Am. 1997, 44 (4), 809-830.
3. Navolanic, P.M.; et al. Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. Leukemia 2003, 17 (3), 499-514.
4. Annemans, L.; et al. Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries. Leuk, Lymphoma 2003, 44 (1), 77-83.
5. Wossmann, W.; et al. Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann. Hematol. 2003, 82 (3), 160-165.
6. Patte, C.; Sakiroglu, O.; Sommelet, D. European experience in the treatment of hyperuricemia. Semin. Hematol. 2001, 38 (4 Suppl 10), 9-12.
7. Brant, J.M. Rasburicase: an innovative new treatment for hyperuricemia associated with tumor lysis syndrome. Clin. J. Oncol. Nurs. 2002, 6 (1), 12-16.
8. Pui, C.H. Rasburicase: a potent uricolytic agent. Expert Opin. Pharmacother. 2002, 3 (4), 433-452.
9. Pui, C.H. Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience. Semin. Hematol. 2001, 38 (4 Suppl 10), 13-21.
10. Easton, J.; Noble, S.; Jarvis, B. Rasburicase. Paediatr. Drugs 2001, 3 (6), 433-437. discussion 438-9.
11. Bayol, A.; et al. Modification of a reactive cysteine explains differences between rasburicase and Uricozyme, a natural Aspergillus flavus uricase. Biotechnol. Appl. Biochem. 2002, 36 (Pt 1), 21-31.
12. Pui, C.H.; et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J. Clin. Oncol. 2001,19 (3), 697-704.
13. Mahmoud, H.H.; et al. Advances in the management of malignancy-associated hyperuricaemia. Br. J. Cancer 1998, 77 (Suppl 4), 18-20.
14. Bowman, W.P.; et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study. J. Clin. Oncol. 1996, 14 (4), 1252-1261.
15. Pui, C.H.; et al. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia 2001, 15 (10), 1505-1509.
16. Goldman, S.C.; et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001, 97 (10), 2998-3003.
17. Bosly, S.; et al. Recombinant urate oxidase (Rasburicase) is safe and effective in managing hyperuricemia in children and adults: results of a multinational compassionate-use trial. ASCO 2002. Abstract 2187, 2002.
18. Annemans, L.; et al. Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. Support, Care Cancer 2003, 11 (4), 249-257.